On November 4, Livemint reported that private equity investors Blackstone and Advent International are in separate talks to buy a controlling stake in Suven Pharmaceuticals.

Moneycontrol first reported on September 7 that the promoters of Suven Pharma have been evaluating options to sell a stake in the company and had hired an investment bank as an advisor. The promoters own 60% of Suven Pharma with a market capitalisation of Rs 6,378 crore.

The sale of at least half the stake would take the deal size to over Rs 3,000 crore, followed by a 26% public offering, which, if successful, could cost the final buyer an additional Rs 1,600-1,700 crore, the report said.

Moneycontrol had earlier reported that the promoter group was exploring its sales plan ahead of the launch of Suven Pharmaceuticals on February 12, 2020.